Dow Corning will present new silicones for topical ingredients, topical excipients, transdermal adhesives, and oral APIs at booth 5R31.

Lucideon announced that it is investing £1.5 million to expand its headquarters to include pharmaceutical quality-control testing laboratories.

Manufacturing drugs from biological sources sometimes can't be rushed, even when a rare disease becomes more widespread.

The recovery of an occasional mold does not merit any particular concern. On the other hand, evidence of mold proliferation indicative of infection of facilities or equipment must be taken seriously and requires the prompt implementation of corrective and preventive actions.

AAPS supports graduate-level programs impacted by cutbacks in funding and resources.

West Pharmaceutical Services announced that they will form a new facility in Ireland for the production of insulin injector cartridge packaging components.

Inversions in the pharmaceutical sector could become less lucrative as a result of new tax laws.

Baxter International announced it will form a R&D center in Cambridge, Massachusetts for its new biopharmaceutical company, Baxalta.

NIH seeks new therapeutic products to bolster the protective properties of vaccines.

Johnson & Johnson announced the acquisition of Alios BioPharma to expand their portfolio of therapeutics for viral infections.

A new Thomson Reuters BioWorld report outlines the more than 700 biosimilars that are currently in development and the emerging business opportunities that exist in the biopharmaceutical space.

SCHOTT will present the adaptiQ ready-to-use vials, syriQ prefilled syringes, and the TopPac Polymer syringes at CPhI Worldwide 2014 in Paris.

Quality is a matter of culture more than metrics. In this opinion article, the author presents arguments for an FDA Dean's List as a means to nurture a quality culture within the industry.

Partnership is awarded for licensing of low-cost vaccine for the treatment of bacterial meningitis.

In response to the Ebola outbreak, EMA has started reviewing Ebola treatments in the development pipeline.

In a highlight from the second annual "CPhI 2014 Expert Industry Annual Report: Part I," Vijay Shah of Piramal Enterprises discusses the benefits of adopting greener practices.

CHMP has recommended 15 new medicines for approval and three extensions of indication.

International Organization for Standardization's environmental management standard 14001 has entered the draft stage, allowing public commentary on revisions.

Global Controlled Release Alliance, a partnership between Dow Pharma & Food Solutions and Colorcon, will present METHOCEL DC2 compressible hydroxypropyl methylcellulose at CPhI Worldwide 2014.

NIH continues funding for tissue chips to be used in the development of therapeutics.

USP expresses its support for a consensus-based global approach to the naming of biologics.

FDA report details risk mitigation projects.

Formulation will utilize Catalent?s OSDrC OptiDose multicore drug-delivery platform.

Meeting increasing expectations and escalating regulatory requirements to protect patients.

Acorda Therapeutics acquired Civitas Therapeutics for $525 million, giving Acorda all the rights to CVT-301, a Phase III candidate for off episodes of Parkinson's disease.

The campaign supports pharmaceutical growth in India and serves to highlight the value proposition that Indian pharmaceuticals present.

AstraZeneca's global biologics research group, MedImmune, received FDA Fast Track designation for MEDI3902, for the prevention of nosocomial pneumonia.

AdPack is an efficient, economical, and safe solution for the protection of moisture-sensitive pharmaceuticals, such as tablets and capsules, inside the packaging.